Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 29, 2012 (14 years ago)

Tacrolimus

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed USP Content Uniformity Requirements: OOS result reported on retained samples.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Mylan, Tacrolimus Capsules 0.5 mg, 100 count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 NDC 0378-2045-01

Affected NDC 0378-2045-01

Compare with the code on your package — it is the most precise check available.

Drug: Tacrolimus

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tacrolimus
NDC 00378-2045
.5 mg/1 Capsule
Oral
Mylan Pharmaceuticals Inc. Rx
Recalling firm
Mylan LLC.
NDC code
0378-2045-01
Origin
PR, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-066-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tacrolimus recalls

See all
Class I · High risk

Prograf (tacrolimus)

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk

Astagraf XL

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023

Other recalls by Mylan LLC.

All 2012 recalls
Class II · Moderate risk

Temozolomide Capsules

Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Terminated Failed specification Mylan LLC. NDC 0378-5265-98 D-0444-2017
Class II · Moderate risk

Temozolomide Capsules

Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Terminated Failed specification Mylan LLC. NDC 0378-5264-98 D-0443-2017
Class II · Moderate risk

Temozolomide Capsules

Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Terminated Failed specification Mylan LLC. NDC 0378-5263-98 D-0442-2017
Class II · Moderate risk

Temozolomide Capsules

Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Terminated Failed specification Mylan LLC. NDC 0378-5262-98 D-0441-2017